Dendritic cell vaccine for HPV type 6 recurrent respiratory papillomatosis
Part of Ear, nose & throat, Infections clinical trials.
This Phase 1 trial is testing a vaccine made from your own immune cells (dendritic cells) that may help your body fight the virus causing recurrent papillomas in your voice box. It is for people whose papillomas are caused by HPV type 6, who have had at least one recurrence in the past year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of recurrent respiratory papillomatosis (RRP) with papillomas growing in your larynx (voice box).
- Your papillomas are caused by human papillomavirus (HPV) type 6.
- You are in good enough general health to be up and about (ECOG score 0 or 1).
- You have adequate blood cell counts (white cells, red cells, platelets) as shown by lab tests.
- You must not have an autoimmune disease, use high-dose steroids, or be pregnant/breastfeeding.
- You must not have used other investigational treatments or vaccines for RRP in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests how well pembrolizumab plus lenvatinib can treat respiratory papillomas that have spread to the lungs. It may help people whose lung disease is caused by human papillomavirus (HPV).
This trial tests if people with recurrent respiratory papillomatosis (growths in the airway caused by HPV) can safely get more doses of the study drug Zopa and checks if the virus spreads after treatment. It may help people who have already tried Zopa or are considering it for the first time.
This Phase 2 study tests whether giving a less intense (de-escalated) radiation plan can work for certain people with HPV-related oropharyngeal throat cancer. It uses HPV blood testing and scans to help guide treatment, aiming to keep cancer control while reducing treatment side effects.
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
This trial tests a special type of immune cell therapy for advanced throat cancer tied to HPV infection. Your own immune cells are reprogrammed in a lab to better attack cancer cells, then given back to you. It aims to help people whose cancer has not responded to standard treatments.
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
Hear when a new Recurrent Respiratory Papillomatosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.